IDDM/AnergiX
Latest Information Update: 04 Nov 2002
Price :
$50 *
At a glance
- Originator Corixa Corporation
- Class
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 04 Nov 2002 Discontinued - Preclinical for Type-1 diabetes mellitus in USA (unspecified route)
- 21 Nov 2000 No-Development-Reported for Type-1 diabetes mellitus in USA (Unknown route)
- 03 May 1995 Preclinical development for Type-1 diabetes mellitus in USA (Unknown route)